Duke University

The Uab Research Foundation

Los Alamos National Security, LLC

University of Alabama

Leland Stanford Junior University

National Institutes of Health, a Component of the US Dept. of Health & Human Services

University of Pennsylvania

Boston University

Triad National Security, LLC

University of California

Feng Gao

George M Shaw

Barton F Haynes

Beatrice H Hahn

Hua-Xin Liao

Bette T Korber

Ying Ying Li

Julie Decker

Peter D Kwong

John R Mascola

Tongqing Zhou

Thomas B Kepler

Scott D Boyd

Rebecca M Lynch

Denise Kothe

M Anthony Moody

Peter T Hraber

Georgia D Tomaras

Stephen M Smith

Preston A Marx, Jr

David C Montefiori

Denise L Monti

Sallie Permar

Chang Yong Lu

Marie Claude Georges-Courbot

The invention provides compositions and methods to induce and boost antibody response, including but not limited to IgG responses binding to HIV-1 in a subject in need thereof, wherein the induced/boosted plasma level of the antibody responses, for example V3 and/or CD4 binding site antibody responses, is over a threshold level and is associated with reduced risk of maternal-to-child-transmission (MTCT) of HIV-1.

Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

Consensus/ancestral immunogens

The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).

Antibody evolution immunogens

In certain aspects the invention provides HIV-1 immunogens, including envelopes (CH505) and selections therefrom, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Swarm immunization with envelopes from CH505

The invention relates to HIV-1 envelope polypeptides comprising the consensus envelope of SEQ ID NO: 35, compositions comprising these envelopes and methods for using same.

Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses

Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins

The nucleotide sequences of the genomes of eleven molecular clones for non-subtype B isolates of human immunodeficiency virus type 1 are disclosed. The invention relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and as immunogens.

Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1

The nucleotide sequence and deduced amino acid sequences of the complete genome of a simian immunodeficiency virus isolate from a red-capped mangabey are disclosed. The invention relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and as immunogens.

Complete genome sequence of a simian immunodeficiency virus from a red-capped mangabey

Growing community of inventors

Durham, NC, United States of America

Feng Gao